In recent decades, rapid progression of monoclonal antibody (mAb) development has culminated in approvals for more than one hundred therapeutics in the United States. mAbs enhance the immune response ...

Data on the poly (ADP-ribose) glycohydrolase (PARG) inhibitor SYX-3759, being investigated for the treatment of homologous recombination deficient (HRD) malignancies, were recently discussed by ...

Telomir Pharmaceuticals (TELO) announced new in vitro findings showing that its investigational compound Telomir-1 kills aggressive human leukemia ...

One in four safety-related failures are due to central nervous system (CNS) toxicity. | One in four safety-related failures are due to central nervous system (CNS) toxicity.

The in-vitro toxicology testing market is primed for growth due to increasing demands for safer drugs and chemicals, ...

Medical device manufacturers use cytotoxicity testing to help prove that devices that come into contact with the human body are biocompatible. Testing results are critical for gaining market access, ...

Findings expand Telomir-1’s oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL / ...

Before a drug candidate can be tested in humans, its safety and efficacy must be explored in preclinical studies. These studies can either be ‘in vitro’, Latin for “within the glass” and referring to ...

A Long Island nurse is sharing a message of action in the face of a frightening genetic finding. She learned she was positive for the BRCA mutation, which increases the risk of cancers, but she took ...

Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in patients with locally-advanced or metastatic refractory solid tumors NRM-823 is a T cell ...